Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedMar 10, 2026
DataAggregated Company Financials
Companies21
  • 7D3.2%
  • 3M-15.6%
  • 1Y-47.5%
  • YTD-21.1%

In the last week, the Healthcare industry is up 1.1%, with Novo Nordisk up 4.6%. During this same period, the Zealand Pharma underperformed, falling 36%. In contrast, the industry has lost 52% in the last 12 months. As for the next few years, earnings are expected to grow by 5.0% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 10 Mar 2026DKK 1.5tDKK 448.2bDKK 131.1b17.1x11.8x3.4x
Thu, 05 Feb 2026DKK 1.8tDKK 447.6bDKK 135.2b17.3x13.5x4.1x
Sat, 03 Jan 2026DKK 2.0tDKK 453.8bDKK 136.9b17x14.3x4.3x
Mon, 01 Dec 2025DKK 1.9tDKK 454.1bDKK 137.0b17.5x14x4.2x
Wed, 29 Oct 2025DKK 2.0tDKK 447.7bDKK 141.8b18.1x13.9x4.4x
Fri, 26 Sep 2025DKK 2.1tDKK 447.5bDKK 141.7b18.1x14.7x4.7x
Sun, 24 Aug 2025DKK 2.1tDKK 447.3bDKK 141.7b24.9x14.8x4.7x
Tue, 22 Jul 2025DKK 2.3tDKK 423.1bDKK 124.5b29.7x18.4x5.4x
Thu, 19 Jun 2025DKK 2.6tDKK 423.6bDKK 124.6b30.4x20.9x6.1x
Sat, 17 May 2025DKK 2.4tDKK 424.4bDKK 125.1b23.5x18.8x5.5x
Mon, 14 Apr 2025DKK 2.3tDKK 409.3bDKK 121.3b21.9x19x5.6x
Wed, 12 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b25.1x23.4x6.9x
Fri, 07 Feb 2025DKK 3.4tDKK 408.2bDKK 118.3b28.3x28.3x8.2x
Sun, 05 Jan 2025DKK 3.4tDKK 387.5bDKK 111.3b30.3x30.3x8.7x
Tue, 03 Dec 2024DKK 4.0tDKK 387.4bDKK 111.3b31.5x36x10.3x
Thu, 31 Oct 2024DKK 4.0tDKK 372.2bDKK 107.2b33.6x37.2x10.7x
Sat, 28 Sep 2024DKK 4.1tDKK 371.9bDKK 107.1b36.5x38.4x11.1x
Mon, 26 Aug 2024DKK 4.7tDKK 371.6bDKK 107.0b36.6x43.6x12.6x
Wed, 24 Jul 2024DKK 4.7tDKK 355.3bDKK 106.2b36.6x44.1x13.2x
Fri, 21 Jun 2024DKK 5.0tDKK 355.3bDKK 106.2b34.6x46.9x14x
Sun, 19 May 2024DKK 4.6tDKK 355.3bDKK 106.2b37.8x43.2x12.9x
Tue, 16 Apr 2024DKK 4.5tDKK 341.3bDKK 99.7b33.8x45.1x13.2x
Thu, 14 Mar 2024DKK 4.7tDKK 341.2bDKK 99.6b39.7x46.7x13.6x
Sat, 10 Feb 2024DKK 4.3tDKK 340.0bDKK 98.5b33.1x43.4x12.6x
Mon, 08 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.2x41.7x11.7x
Wed, 06 Dec 2023DKK 3.6tDKK 320.5bDKK 90.0b33.4x39.7x11.2x
Fri, 03 Nov 2023DKK 3.7tDKK 318.8bDKK 90.3b28.5x40.5x11.5x
Sun, 01 Oct 2023DKK 3.4tDKK 305.5bDKK 82.2b33.6x41.4x11.1x
Tue, 29 Aug 2023DKK 3.4tDKK 305.2bDKK 82.1b35.8x41.8x11.2x
Thu, 27 Jul 2023DKK 2.9tDKK 287.1bDKK 75.5b36.9x38.5x10.1x
Sat, 24 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b39.9x39.7x10.4x
Mon, 22 May 2023DKK 3.2tDKK 287.1bDKK 75.5b41x41.9x11x
Wed, 19 Apr 2023DKK 3.2tDKK 272.6bDKK 68.5b44x46.4x11.7x
Fri, 17 Mar 2023DKK 2.7tDKK 292.6bDKK 69.2b37.7x39.4x9.3x
Price to Earnings Ratio

39.4x


Total Market Cap: DKK 2.7tTotal Earnings: DKK 69.2bTotal Revenue: DKK 292.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 32.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.6x which is lower than its 3-year average PE of 32.5x.
  • The 3-year average PS ratio of 9.2x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 24% per year over the last three years.
  • Revenues for these companies have grown 15% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-0.94%
Healthcare3.24%
Pharma6.75%
Healthcare Services4.66%
Life Sciences-4.01%
Healthtech-4.25%
Medical Equipment-5.86%
Biotech-11.02%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 431x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 85% over the next 5 years.
  • This is better than its past earnings decline of 100% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 2.5% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 254.507.4%
+DKK 77.5b		-53.7%PE11x
ALK B ALK-AbellóDKK 221.600.7%
+DKK 354.5m		60.2%PE41x
SMSMED Scandinavian Medical SolutionsDKK 3.374.7%
+DKK 4.2m		-37.6%PE3604.1x
PEG Pharma Equity GroupDKK 0.0951.7%
+DKK 2.0m		-32.4%PB2.9x
STENO StenocareDKK 1.271.6%
+DKK 863.9k		225.6%PS7.8x

Latest News

AMBU B
DKK 74.50
Ambu
7D
-5.4%
1Y
-38.7%

AMBU B: Share Repurchase Mandate And Lowered Fair Value Will Support Upside

Analysts have trimmed their price target on Ambu by DKK 12 to reflect updated assumptions on fair value, discount rates and earnings expectations following recent research commentary. Analyst Commentary Bullish Takeaways Bullish analysts view the revised DKK 12 lower price target as still consistent with a supportive fair value range.
HLUN B
DKK 38.10
H. Lundbeck
7D
-2.5%
1Y
-3.8%

HLUN B: Migraine Pipeline Progress Will Support Constructive Medium Term Upside Potential

Analysts have raised their H. Lundbeck price target from DKK 44.95 to DKK 46.13, citing updated assumptions around revenue growth, profit margins and future P/E as the main factors behind the change.
GUBRA
DKK 355.40
Gubra
7D
-8.2%
1Y
-23.6%
ZEAL
DKK 255.80
Zealand Pharma
7D
-30.4%
1Y
-49.6%
COLO B
DKK 448.80
Coloplast
7D
-7.0%
1Y
-39.9%
DEMANT
DKK 188.40
Demant
7D
-4.2%
1Y
-26.7%
NOVO B
DKK 254.50
Novo Nordisk
7D
7.4%
1Y
-53.7%

NOVO B: Future Returns Will Rely On Oral Obesity And GLP-1 Tablet Expansion

The updated analyst price target for Novo Nordisk has shifted from DKK 376.59 to DKK 330.95, with analysts citing more measured assumptions on revenue growth, profit margins and future P/E as key drivers of the change. Analyst Commentary Analysts revisiting their assumptions on Novo Nordisk are effectively marking the shares to more conservative expectations, with the updated price target of DKK 330.95 reflecting a reset in what they are willing to pay for the company’s earnings profile.
BAVA
DKK 181.95
Bavarian Nordic
7D
-5.6%
1Y
9.9%

BAVA: Buybacks And Latin America Vaccine Deal Will Drive Future Upside

Analysts have maintained their DKK 250 price target on Bavarian Nordic, citing only minor adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E as the reasons for this stable assessment. What's in the News CEO Paul Chaplin plans to step down for personal reasons, and the Board has agreed that he will stay in the role through the end of 2026 or until a successor is appointed.
GMAB
DKK 1,725.00
Genmab
7D
-7.4%
1Y
13.3%

GMAB: 2026 Catalyst Events And AI Adoption Will Shape Outlook

Genmab's analyst fair value estimate has moved up from DKK 2,182 to DKK 2,238, as analysts factor in higher long term revenue growth assumptions, a higher future P/E and recent price target revisions around DKK 2,400 to DKK 2,500, even as they temper near term expectations for Epkinly and margins. Analyst Commentary Recent research points to a more nuanced view of Genmab, with several firms adjusting their price targets and models following the latest earnings, product updates and acquisition activity.
PEG
DKK 0.095
Pharma Equity Group
7D
1.7%
1Y
-32.4%
STENO
DKK 1.27
Stenocare
7D
1.6%
1Y
225.6%
ALK B
DKK 221.60
ALK-Abelló
7D
0.7%
1Y
60.2%

ALK B: Future Returns Will Rely On Expanded Anaphylaxis Indications And Stronger Margins

Analysts have nudged their price target on ALK-Abelló up from DKK 249 to DKK 255, reflecting updated assumptions that combine slightly lower expected revenue growth with a higher projected profit margin and a modestly lower future P/E multiple. What's in the News ALK Abelló issued earnings guidance for 2026, indicating an expectation of continued double digit revenue growth and higher earnings, with revenue projected to grow 11 to 15% in local currencies (company guidance).
SMSMED
DKK 3.37
Scandinavian Medical Solutions
7D
4.7%
1Y
-37.6%

Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)

Jan 27
Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)
BRAINP
DKK 0.0032
Brain+
7D
14.3%
1Y
-94.8%
VIRO
DKK 11.90
ViroGates
7D
0.4%
1Y
33.0%
STRAP
DKK 580.00
Strategic Partners
7D
3.2%
1Y
-22.8%